9 hours Ago By ABMN Staff
Invesco Ltd. trimmed its holdings in Tandem Diabetes Care, Inc. ( NASDAQ:TNDM – Free Report ) by 35.
5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 204,890 shares of the medical device company’s stock after selling 112,695 shares during the quarter. Invesco Ltd.
owned about 0.31% of Tandem Diabetes Care worth $7,380,000 as of its most recent SEC filing. Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company.
McIlrath & Eck LLC acquired a new position in shares of Tandem Diabetes Care in the 3rd quarter valued at $52,000. Franklin Resources Inc. increased its stake in Tandem Diabetes Care by 95.
6% in the third quarter. Franklin Resources Inc. now owns 26,785 shares of the medical device company’s stock valued at $1,136,000 after purchasing an additional 13,088 shares during the period.
JPMorgan Chase & Co. raised its holdings in shares of Tandem Diabetes Care by 134.6% in the third quarter.
JPMorgan Chase & Co. now owns 197,583 shares of the medical device company’s stock valued at $8,379,000 after buying an additional 113,355 shares during the last quarter. Park Avenue Securities LLC boosted its stake in shares of Tandem Diabetes Care by 34.
5% during the fourth quarter. Park Avenue Securities LLC now owns 8,914 shares of the medical device company’s stock worth $321,000 after buying an additional 2,286 shares during the period. Finally, LVW Advisors LLC grew its holdings in shares of Tandem Diabetes Care by 13.
8% during the fourth quarter. LVW Advisors LLC now owns 7,798 shares of the medical device company’s stock worth $281,000 after buying an additional 944 shares during the last quarter. Analyst Ratings Changes Several equities analysts have issued reports on the stock.
Canaccord Genuity Group reissued a “buy” rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Barclays dropped their price objective on Tandem Diabetes Care from $60.
00 to $53.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Mizuho assumed coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th.
They set a “neutral” rating and a $20.00 target price on the stock. Royal Bank of Canada cut their price target on shares of Tandem Diabetes Care from $65.
00 to $55.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. Finally, Sanford C.
Bernstein downgraded shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $35.00 to $25.00 in a report on Friday, February 28th.
Eight equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $43.88.
Tandem Diabetes Care Stock Up 6.6 % TNDM stock opened at $17.67 on Friday.
The company has a 50 day moving average price of $20.46 and a two-hundred day moving average price of $29.44.
The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.
90. The stock has a market capitalization of $1.18 billion, a P/E ratio of -9.
16 and a beta of 1.52. Tandem Diabetes Care, Inc.
has a one year low of $15.75 and a one year high of $53.69.
Insider Transactions at Tandem Diabetes Care In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of the business’s stock in a transaction on Friday, March 7th. The shares were bought at an average price of $18.12 per share, with a total value of $190,948.
56. Following the completion of the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56.
This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink . Insiders own 2.
20% of the company’s stock. Tandem Diabetes Care Profile ( Free Report ) Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Featured Stories Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. ( NASDAQ:TNDM – Free Report ).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter ..
